Neurologic complications of chemotherapy and radiation therapy

CONTINUUM Lifelong Learning in Neurology

Volumn 21, Issue 2, 2015, Pages 429-451

  Nolan, Craig P ^a   Deangelis, Lisa M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CYTARABINE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE; VASCULOTROPIN INHIBITOR; VINCA ALKALOID; VINCRISTINE;

ACUTE BRAIN DISEASE; ACUTE PANCEREBELLAR SYNDROME; ASEPTIC MENINGITIS; AUTONOMIC NEUROPATHY; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM DISEASE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CRANIAL NERVE INJURY; DEMENTIA; EARLY DIAGNOSIS; ELECTRIC SHOCK; ENDOCRINE DISEASE; HEADACHE; HUMAN; LEUKOENCEPHALOPATHY; LHERMITTE SYMPTOM; MALIGNANT NEOPLASTIC DISEASE; MENINGITIS; MENTAL FOGGINESS; MOTOR NEURON SYNDROME; MYOPATHY; NERVOUS SYSTEM INJURY; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUROPATHY; NEUROTOXICITY; OTOTOXICITY; PERIPHERAL NERVE INJURY; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; QUALITY OF LIFE; RADIATION NECROSIS; REVIEW; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SPINAL CORD DISEASE; TELANGIECTASIA; VASCULAR DISEASE; VISUAL IMPAIRMENT; WALLERIAN DEGENERATION; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; COMPLICATION; NEOPLASMS; NERVOUS SYSTEM DISEASES; RADIATION; RADIATION INJURIES;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; RADIATION; RADIATION INJURIES;

EID: 84926465867     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000464179.81957.51     Document Type: Review

References (41)

1. DeAngelis LM, Posner JP. Neurologic complications of cancer. New York: Oxford University Press, 2009.
2. Soffietti R, Trevisan E, Ruda R. Neurologic complications of chemotherapy and other newer and experimental approaches. Handb Clin Neurol 2014;121:1199-1218. doi:10. 1016/B978-0-7020-4088-7. 00080-8.
3. Sul JK, Deangelis LM. Neurologic complications of cancer chemotherapy. Semin Oncol 2006;33(3):324-332. doi:10. 11053/j. seminoncol. 2006. 03. 006.
4. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature. Blood 2008;112(5): 1593-1599. doi:10. 1182/blood-2008-04-149385.
5. Zara G, Ermani M, Rondinone R, et al. Thalidomide and sensory neurotoxicity: A neurophysiological study. J Neurol Neurosurg Psychiatry 2008;79(11):1258-1261. doi:10. 1136/jnnp. 2008. 147892.
6. Cavaletti G, Cornblath DR, Merkies IS, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Ann Oncol 2013;24(2): 454-462. doi:10. 1093/annonc/mds329.
7. Binda D, Vanhoutte EK, Cavaletti G, et al. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). Eur J Cancer 2013;49(13):2910-2918. doi:10. 1016/j. ejca. 2013. 04. 004.
8. Leal AD, Qin R, Atherton PJ, et al. North Central Cancer Treatment Group/Alliance Trial N08CAVthe use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study. Cancer 2014;120(12):1890-1897. doi:10. 1002/cncr. 28654.
9. Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 2014;32(10):997-1005. doi:10. 1200/JCO. 2013. 52. 0536.
10. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA 2013;309(13):1359-1367. doi:10. 1001/jama. 2013. 2813.
11. Gewandter JS, Mohile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer 2014;22(7):1807-1814. doi:10. 1007/s00520-014-2158-7.
12. Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 2014;32(9):949-959. doi:10. 1200/JCO. 2013. 53. 0808.
13. Correa DD, ShiW, Abrey LE, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol 2012;14(1):101-108. doi:10. 1093/neuonc/nor186.
14. Szabatura AH, Cirrone F, Harris C, et al. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center (published online ahead of print March 24, 2014). J Oncol Pharm Pract 2014. doi:10. 1177/1078155214527143.
15. Sclafani F, Giuseppe G, Mezynksi J, et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer. J Clin Oncol 2012;30(26):e257Ye259. doi:10. 1200/JCO. 2011. 38. 8942.
16. Femia G, Hardy TA, Spies JM, Horvath LG. Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: A case report and literature review. Asia Pac J Clin Oncol 2012;8(2):115-122. doi:10. 1111/j. 1743-7563. 2012. 01544. x.
17. Seet RC, Rabinstein AA, Lindell PE, et al. Cerebrovascular events after bevacizumab treatment: An early and severe complication. Neurocrit Care 2011;15(3):421-427. doi:10. 1007/s12028-011-9552-5.
18. Fraum TJ, Kreisl TN, Sul J, et al. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol 2011;105(2):281-289. doi:10. 1007/s11060-011-0579-4.
19. Khasraw M, Holodny A, Goldlust SA, DeAngelis LM. Intracranial hemorrhage in patients with cancer treated with bevacizumab: The Memorial Sloan-Kettering experience. Ann Oncol 2012;23(2):458-463. doi:10. 1093/annonc/mdr148.
20. Ahles TA. Brain vulnerability to chemotherapy toxicities. Psychooncology 2012;21(11): 1141-1148. doi:10. 1002/pon. 3196.
21. Mandelblatt JS, Stern RA, Luta G, et al. Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol 2014;32(18): 1909-1918. doi:10. 1200/JCO. 2013. 54. 2050.
22. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010;28(29):4434-4440. doi:10. 1200/JCO. 2009. 27. 0827.
23. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 2014;26(1):102-113. doi:10. 3109/09540261. 2013. 864260.
24. Greene-Schloesser D, Robbins ME, Peiffer AM, et al. Radiation-induced brain injury: A review. Front Oncol 2012;2:73. doi:10. 3389/fonc. 2012. 00073.
25. Belka C, Budach W, Kortmann RD, Bamberg M. Radiation induced CNS toxicityVmolecular and cellular mechanisms. Br J Cancer 2001;85(9):1233-1239. doi:10. 1054/bjoc. 2001. 2100.
26. Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy: A comprehensive review. Expert Rev Neurother 2013;13(4):389-403. doi:10. 1586/ern. 13. 7.
27. Nasseri M, Gahramanov S, Netto JP, et al. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro Oncol 2014;16(8): 1146-1154. doi:10. 1093/neuonc/not328.
28. Chu HH, Choi SH, Ryoo I, et al. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: Comparison study of standard and high-b-value diffusion-weighted imaging. Radiology 2013;269(3):831-840. doi:10. 1148/radiol. 13122024.
29. Schuttrumpf LH, Niyazi M, Nachbichler SB, et al. Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery aloneor in combination withwhole brain radiation therapy for 1-3 cerebral metastases. Radiat Oncol 2014;9:105. doi:10. 1186/1748-717X-9-105.
30. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006;295(21):2483-2491. doi:10. 1001/jama. 295. 21. 2483.
31. Valadao J, Pearl J, Verma S, et al. Hyperbaric oxygen treatment for post-radiation central nervous system injury: A retrospective case series. Undersea Hyperb Med 2014;41(2):87-96.
32. Yonezawa S, Miwa K, Shinoda J, et al. Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis. J Neurooncol 2014;119(1):101-109. doi:10. 1007/s11060-014-1453-y.
33. Lee YW, Cho HJ, Lee WH, Sonntag WE. Whole brain radiation-induced cognitive impairment: pathophysiological mechanisms and therapeutic targets. Biomol Ther (Seoul) 2012;20(4):357-370. doi:10. 4062/biomolther. 2012. 20. 4. 357.
34. Thiessen B, DeAngelis LM. Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting. Arch Neurol 1998;55(5):705-710. doi:10. 1001/archneur. 55. 5. 705.
35. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 2009;10(11):1037-1044. doi:10. 1016/S1470-2045(09)70263-3.
36. Greene-Schloesser D, Moore E, Robbins ME. Molecular pathways: radiation-induced cognitive impairment. Clin Cancer Res 2013;19(9):2294-2300. doi:10. 1158/1078-0432. CCR-11-2903.
37. Monje M, Dietrich J. Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behav Brain Res 2012;227(2):376-379. doi:10. 1016/j. bbr. 2011. 05. 012.
38. Wong-Goodrich SJ, Pfau ML, Flores CT, et al. Voluntary running prevents progressive memory decline and increases adult hippocampal neurogenesis and growth factor expression after whole-brain irradiation. Cancer Res 2010;70:9329-9338. doi:10. 1158/0008-5472. CAN-10-1854. 450 www. ContinuumJournal. com
39. Mathews MS, Peck WW, Brant-Zawadzki M. Brown-Sequard syndrome secondary to spontaneous bleed from postradiation cavernous angiomas. AJNR Am J Neuroradiol 2008;29(10):1989-1990. doi:10. 3174/ajnr. A1158.
40. Li CS, Schminke U, Tan TY. Extracranial carotid artery disease in nasopharyngeal carcinoma patients with post-irradiation ischemic stroke. Clin Neurol Neurosurg 2010; 112(8):682-686. doi:10. 1016/j. clineuro. 2010. 05. 007.
41. Kerklaan JP, Lycklama á Nijeholt GJ, Wiggenraad RG, et al. SMART syndrome: A late reversible complication after radiation therapy for brain tumours. J Neurol 2011;258(6):1098-1104. doi:10. 1007/s00415-010-5892-x.